Download Files:

SCH 546738

$320$1,890

Products Details

Product Description

– SCH 546738 is a potent, orally active and non-competitive CXCR3 antagonist, the affinity constant (Ki) of SCH 546738 binding to human CXCR3 receptor is determined to be 0.4 nM in multiple experiments.

Web ID

– HY-10017

Storage Temperature

– -20°C, 3 years; 4°C, 2 years (Powder)

Shipping

– Room Temperature

Applications

– COVID-19-immunoregulation

Molecular Formula

– C23H31Cl2N7O

References

– [1]Zhang X, et al. CXC chemokine receptor 3 promotes steatohepatitis in mice through mediating inflammatory cytokines, macrophages and autophagy. J Hepatol. 2016 Jan;64(1):160-70.|[2]Yue C, et al. STAT3 in CD8<sup>+</sup> T Cells Inhibits Their Tumor Accumulation by Downregulating CXCR3/CXCL10 Axis. Cancer Immunol Res. 2015 Aug;3(8):864-870.|[3]Jenh CH, et al. A selective and potent CXCR3 antagonist SCH 546738 attenuates the development of autoimmune diseases and delays graft rejection. BMC Immunol. 2012 Jan 10;13:2.

CAS Number

– 906805-42-3

Molecular Weight

– 492.44

Compound Purity

– 98.71

SMILES

– O=C(N)C1=NC(Cl)=C(N2CCN(C3CCN(CC4=CC=C(Cl)C=C4)CC3)[C@@H](CC)C2)N=C1N

Clinical Information

– No Development Reported

Research Area

– Inflammation/Immunology; Endocrinology

Solubility

– DMSO : 4.5 mg/mL (ultrasonic)|H2O : 1 mg/mL (ultrasonic;warming;heat to 80°C)

Target

– CXCR

Isoform

– CXCR3

Pathway

– GPCR/G Protein;Immunology/Inflammation

Product type

– Reference compound

Disclaimer: All products are for research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation.

My Cart
Close Wishlist
Close Recently Viewed
Categories

Please fill out this form to request the file. We will send it to your Email address shortly. Thanks.

Please enable JavaScript in your browser to complete this form.

Please fill out this form to request the pricing.
We will send it to your email address shortly.
Thanks.

Please enable JavaScript in your browser to complete this form.